These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28271699)

  • 41. Assessing ovarian response: antral follicle count versus anti-Müllerian hormone.
    Fleming R; Seifer DB; Frattarelli JL; Ruman J
    Reprod Biomed Online; 2015 Oct; 31(4):486-96. PubMed ID: 26283017
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ovarian reserve and PGD treatment outcome in women with myotonic dystrophy.
    Srebnik N; Margalioth EJ; Rabinowitz R; Varshaver I; Altarescu G; Renbaum P; Levi-Lahad E; Weintraub A; Eldar-Geva T
    Reprod Biomed Online; 2014 Jul; 29(1):94-101. PubMed ID: 24813161
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A predictive formula for selecting individual FSH starting dose based on ovarian reserve markers in IVF/ICSI cycles.
    Zhu M; Wang S; Yi S; Huang X; Meng J; Chen L; Sun H; Zhou J
    Arch Gynecol Obstet; 2019 Aug; 300(2):441-446. PubMed ID: 30976971
    [TBL] [Abstract][Full Text] [Related]  

  • 44. AMH type II receptor and AMH gene polymorphisms are not associated with ovarian reserve, response, or outcomes in ovarian stimulation.
    Cerra C; Newman WG; Tohlob D; Byers H; Horne G; Roberts SA; Mohiyiddeen L
    J Assist Reprod Genet; 2016 Aug; 33(8):1085-91. PubMed ID: 27142041
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-Mullerian hormone is a better marker than inhibin B, follicle stimulating hormone, estradiol or antral follicle count in predicting the outcome of in vitro fertilization.
    Kunt C; Ozaksit G; Keskin Kurt R; Cakir Gungor AN; Kanat-Pektas M; Kilic S; Dede A
    Arch Gynecol Obstet; 2011 Jun; 283(6):1415-21. PubMed ID: 21562964
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Change in oocyte yield in repeated in vitro fertilization cycles: effect of ovarian reserve.
    Eppsteiner EE; Sparks AE; Liu D; Van Voorhis BJ
    Fertil Steril; 2014 Feb; 101(2):399-402. PubMed ID: 24331835
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment.
    Andersen AN; Witjes H; Gordon K; Mannaerts B;
    Hum Reprod; 2011 Dec; 26(12):3413-23. PubMed ID: 21954280
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization-intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study.
    Polyzos NP; Nelson SM; Stoop D; Nwoye M; Humaidan P; Anckaert E; Devroey P; Tournaye H
    Fertil Steril; 2013 Aug; 100(2):438-44. PubMed ID: 23602319
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predicting the ovarian response: towards a determinant model and implications for practice.
    Arvis P; Rongières C; Pirrello O; Lehert P
    J Assist Reprod Genet; 2024 Jan; 41(1):213-222. PubMed ID: 37921971
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A single nucleotide polymorphism of bone morphogenic protein-15 is not associated with ovarian reserve or response to ovarian stimulation.
    Cerra C; Oliver J; Roberts SA; Horne G; Newman WG; Mohiyiddeen L
    Hum Reprod; 2014 Dec; 29(12):2832-7. PubMed ID: 25336710
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictive values of anti-müllerian hormone, antral follicle count and ovarian response prediction index (ORPI) for assisted reproductive technology outcomes.
    Ashrafi M; Hemat M; Arabipoor A; Salman Yazdi R; Bahman-Abadi A; Cheraghi R
    J Obstet Gynaecol; 2017 Jan; 37(1):82-88. PubMed ID: 27976974
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is assessment of anti-Müllerian hormone and/or antral follicle count useful in the prediction of ovarian response in expected normal responders treated with a fixed dose of recombinant FSH and GnRH antagonists? A prospective observational study.
    Ganidou MA; Kolibianakis EM; Venetis CA; Gerou S; Makedos GA; Klearchou N; Tarlatzis BC
    Gynecol Endocrinol; 2014 Nov; 30(11):817-21. PubMed ID: 24989633
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of 'normal' early follicular FSH concentrations with unexpected poor or suboptimal response when ovarian reserve markers are reassuring: a retrospective cohort study.
    Del Gallego R; Lawrenz B; Ata B; Kalafat E; Melado L; Elkhatib I; Fatemi H
    Reprod Biomed Online; 2024 Mar; 48(3):103701. PubMed ID: 38309124
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gonadotrophin stimulation for in vitro fertilization significantly alters the hormone milieu in follicular fluid: a comparative study between natural cycle IVF and conventional IVF.
    von Wolff M; Kollmann Z; Flück CE; Stute P; Marti U; Weiss B; Bersinger NA
    Hum Reprod; 2014 May; 29(5):1049-57. PubMed ID: 24608520
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of ovarian reserve markers in prediction of clinical pregnancy.
    Zebitay AG; Cetin O; Verit FF; Keskin S; Sakar MN; Karahuseyinoglu S; Ilhan G; Sahmay S
    J Obstet Gynaecol; 2017 May; 37(4):492-497. PubMed ID: 28421902
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders.
    Yeung TW; Chai J; Li RH; Lee VC; Ho PC; Ng EH
    Fertil Steril; 2014 Jul; 102(1):108-115.e1. PubMed ID: 24796766
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection.
    Arce JC; Andersen AN; Fernández-Sánchez M; Visnova H; Bosch E; García-Velasco JA; Barri P; de Sutter P; Klein BM; Fauser BC
    Fertil Steril; 2014 Dec; 102(6):1633-40.e5. PubMed ID: 25256937
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selective use of corifollitropin for controlled ovarian stimulation for IVF in patients with low anti-Müllerian hormone.
    Nielsen AP; Korsholm AS; Lemmen JG; Sylvest R; Sopa N; Nyboe Andersen A
    Gynecol Endocrinol; 2016 Aug; 32(8):625-628. PubMed ID: 26891977
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Impact of Salpingectomy on Anti-Mullerian Hormone Levels and Ovarian Response of In Vitro Fertilization Patients.
    Gluck O; Tamayev L; Torem M; Bar J; Raziel A; Sagiv R
    Isr Med Assoc J; 2018 Aug; 20(8):509-512. PubMed ID: 30084578
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve.
    Lekamge DN; Lane M; Gilchrist RB; Tremellen KP
    J Assist Reprod Genet; 2008; 25(11-12):515-21. PubMed ID: 18972201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.